620632-73-7Relevant academic research and scientific papers
Potent, selective pyrimidinetrione-based inhibitors of MMP-13
Reiter, Lawrence A.,Freeman-Cook, Kevin D.,Jones, Christopher S.,Martinelli, Gary J.,Antipas, Amy S.,Berliner, Martin A.,Datta, Kaushik,Downs, James T.,Eskra, James D.,Forman, Michael D.,Greer, Elaine M.,Guzman, Roberto,Hardink, Joel R.,Janat, Fouad,Keene, Nandell F.,Laird, Ellen R.,Liras, Jennifer L.,Lopresti-Morrow, Lori L.,Mitchell, Peter G.,Pandit, Jayvardhan,Robertson, Donald,Sperger, Diana,Vaughn-Bowser, Marcie L.,Waller, Darra M.,Yocum, Sue A.
, p. 5822 - 5826 (2007/10/03)
Using SAR from two related series of pyrimidinetrione-based inhibitors, compounds with potent MMP-13 inhibition and >100-fold selectivity against other MMPs have been identified. Despite high molecular weights, c log Ps, and polar surface areas, the compo
Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
-
Page/Page column 31; 32, (2010/02/05)
The present invention relates to triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione; metalloproteinase inhibitors of the formula wherein X, A, Y, B, G, W, and R1 are as defined in the specification, and to pharmaceutical compositions and methods of treating inflammation, cancer and other disorders.
